ABT-263 (Navitoclax)

C-1009 Targets: BCL-2 Synonym: ABT-263; ABT263; ABT 263; Navitoclax Chemical Name/IUPAC:(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide SMILES Code: O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4 Technical Data Product Name: ABT-263 (Navitoclax) Chemical Formula: C47H55ClF3N5O6S3 Moleculer Weight: 974.61 CAS#: 923564-51-6 Appearance: Solid powder Purity: > 99% by HPLC Solubility: Soluble in DMSO Storage: Room temperature for months, or -20ºC for 3 years Description ABT-263 (Navitoclax) is an orally bioavailable, small-molecule antagonist of a subset of BCl-2 (B-cell leukemia 2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents the